首页> 美国卫生研究院文献>other >Modulation of Gut Microbiome Composition and Function in Experimental Colitis Treated with Sulfasalazine
【2h】

Modulation of Gut Microbiome Composition and Function in Experimental Colitis Treated with Sulfasalazine

机译:柳氮磺胺吡啶治疗实验性结肠炎肠道微生物组组成和功能的调节

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Inflammatory bowel disease (IBD) results from alterations in intestinal flora and the immune system. Sulfasalazine (SASP) is a sulfa antimicrobial used to treat IBD in clinic for years. However, how SASP affects gut microbes and its potential functions remains unclear. To investigate the relationships of SASP, IBD, and gut microbiome, we used 2,4,6-trinitrobenzenesulfonic acid (TNBS) to induce experimental colitis in rats, and analyzed the microbiota in the fecal samples, which come from the control group (treated with ethanol + saline), the model group (treated with TNBS-ethanol + saline) and the SASP group (treated with TNBS-ethanol + SASP), with 16S gene sequencing and followed up a subset sample using shotgun sequencing. The study found that SASP treatment could not only restore the TNBS-induced gut dysbiosis, which was proved by the increasing amount of SCFAs-producing bacteria and lactic acid-producing bacteria as well as the decreasing amount of Proteobacteria, but also modulate the dysregulated function of the TNBS-induced colitis to resemble that of the control group, including an increased capacity for basic metabolism (carbohydrate metabolism, citrate cycle) and a decrease in the oxidative stress (riboflavin, sulfur, cysteine) as well as bacterial pathogenesis (cell motility and secretion, bacterial motility proteins, flagellar assembly). Moreover, a higher proportion of Mycoplasma was observed in the SASP group, which may associate with infertility. In all, the study provides insight into specific microbial clades and pathways linked with SASP treatment to elaborate the mechanism for treatment of IBD.
机译:炎症性肠病(IBD)是由肠道菌群和免疫系统改变引起的。柳氮磺吡啶(SASP)是一种磺胺类抗生素,多年来在临床中用于治疗IBD。然而,尚不清楚SASP如何影响肠道微生物及其潜在功能。为了研究SASP,IBD和肠道微生物组之间的关系,我们使用2,4,6-三硝基苯磺酸(TNBS)诱导大鼠实验性结肠炎,并分析了粪便样品中的微生物群(来自对照组)用乙醇+盐水),模型组(用TNBS-乙醇+盐水处理)和SASP组(用TNBS-乙醇+ SASP处理)进行16S基因测序,并使用shot弹枪测序对部分样本进行随访。研究发现,SASP处理不仅可以恢复TNBS引起的肠道营养不良,这可以通过产生SCFAs和乳酸菌的数量增加以及变形杆菌数量的减少来证明,而且可以调节功能失调TNBS诱发的结肠炎的症状与对照组相似,包括增加的基本代谢能力(碳水化合物代谢,柠檬酸盐循环)和氧化应激(核黄素,硫,半胱氨酸)的减少以及细菌的发病机理(细胞运动性)和分泌,细菌运动蛋白,鞭毛组装)。此外,在SASP组中观察到较高比例的支原体,这可能与不孕有关。总之,该研究提供了与SASP治疗相关的特定微生物进化枝和途径的见解,从而阐明了IBD的治疗机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号